---
document_datetime: 2023-09-21 21:19:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_en.pdf
document_name: vaxchora-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7776747
conversion_datetime: 2025-12-30 10:20:02.643421
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                                | Route of administration   | Immediate Packaging                                                                       | Pack size          |
|------------------|-------------------|------------|----------------------------------------------------|---------------------------|-------------------------------------------------------------------------------------------|--------------------|
| EU/1/20/1423/001 | Vaxchora          | -- 1       | Effervescent powder and powder for oral suspension | Oral use                  | Active component: sachet (paper/LDPE/alu/LDPE); Buffer component: sachet (paper/alu/LDPE) | 1 set of 2 sachets |

-- 1 -- 1

1 One dose contains:

4 x 10E8 to 2 x 10E9 viable cells of Vibrio cholerae live, attenuated strain CVD 103-HgR